We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Kisspeptin (KISS1-derived neuropeptide)
A hypothalamic neuropeptide (from the KISS1 gene) that sits at the top of the reproductive hormone axis — it stimulates GnRH neurons to release LH and FSH. It has a genuinely rigorous human-research record, largely from the Dhillo group at Imperial College London: kisspeptin-54 has been tested as an IVF egg-maturation trigger, in hypothalamic amenorrhea, and for sexual/emotional brain processing. Honest framing: this is legitimate investigational science, NOT an approved drug or a dietary supplement, and the grey-market 'libido peptide' sold online is not the supervised clinical product.
Research peptide — not a dietary supplement
Kisspeptin is a research compound, not a regulated dietary supplement. It is typically administered by injection and sold “for research use only.” The evidence below is largely preclinical (animal and in-vitro) or early-stage, so no evidence score is assigned. This page is provided for transparency and education — it is not a recommendation to use. Consult a qualified healthcare provider, and be aware that purity, dosing, and legal status vary by jurisdiction.
What the evidence says
Kisspeptin doesn't have enough studies with structured effect-size data yet to pool a verdict. Browse the studies below for individual findings.
Most evidence is from medium-quality randomised trials published 2009–2026 with a typical study size of 32 participants.
Based on 36 studies · 20 RCTs · 908 total participants
Confidence
Moderate confidenceBy outcome
Kisspeptin has unusually rigorous human research (phase-2 IVF and fMRI RCTs), but it remains an investigational research peptide with no approved consumer use or self-administration data — an emerging score.
14 randomised trials
93% were about Kisspeptin in an audit of 14 of them
Every randomised or controlled trial of Kisspeptin indexed in PubMed, not a hand-picked subset. Meta-analyses and systematic reviews are deliberately excluded from this count: most of them cover many compounds at once, so counting them would inflate it.
PubMed · as of Sep 2026
5 trials ongoing or recruiting · 23 completed on ClinicalTrials.gov
4 of the completed trials have posted results
Registered trials show research momentum for Kisspeptin, not proof of effect — a registration is a plan, and posted results are sponsor-reported, not peer-reviewed. They are never counted toward the evidence rating above.
Browse these trials on ClinicalTrials.govClinicalTrials.gov · as of Nov 2026
Kisspeptin is the protein product of the KISS1 gene, signalling through the KISS1R receptor (also called GPR54) on hypothalamic gonadotropin-releasing-hormone (GnRH) neurons.
It is the principal upstream gatekeeper of the hypothalamic-pituitary-gonadal axis: kisspeptin neurons integrate sex-steroid, metabolic and circadian signals and drive the pulsatile and surge-mode release of GnRH that in turn controls luteinizing hormone (LH) and follicle-stimulating hormone (FSH).
The two research forms are kisspeptin-54 (KP-54, the full-length cleaved peptide) and kisspeptin-10 (KP-10, the C-terminal decapeptide).
The human evidence is real and unusually rigorous for a 'research peptide': controlled studies — mostly from Waljit Dhillo's group at Imperial College London — have shown that a single subcutaneous dose of kisspeptin-54 can trigger final oocyte maturation in IVF, including phase-2 randomized trials in women at high risk of ovarian hyperstimulation syndrome (OHSS), where it produced mature eggs and live births with strikingly low OHSS rates.
Kisspeptin acutely stimulates gonadotropin release in women with hypothalamic amenorrhea (though chronic twice-daily dosing causes tachyphylaxis/desensitization), discriminates hypothalamic from pituitary dysfunction in men with congenital hypogonadotropic hypogonadism, and raises LH and testosterone in hypogonadal men with type 2 diabetes.
Separately, functional-MRI studies show kisspeptin modulates limbic 'sexual and emotional' brain processing and, in a randomized trial, improved sexual brain responses and penile tumescence in men with hypoactive sexual desire disorder (HSDD).
Despite this strong mechanistic and early-clinical base, kisspeptin is NOT an approved medicine and is NOT a regulated dietary supplement — it remains investigational, used in registered trials and academic IVF protocols.
The honest caution: a grey-market 'kisspeptin' is sold online as a libido/testosterone peptide, but self-administration is unstudied, sourcing is unregulated and potentially impure, there is no long-term safety data outside supervised trials, and the marketing hype runs well ahead of what the supervised human evidence actually supports.
Kisspeptin binds KISS1R (GPR54) on hypothalamic GnRH neurons, the upstream gatekeeper of the reproductive axis. This stimulates GnRH release, driving downstream pituitary gonadotropin (LH/FSH) secretion.
By stimulating an endogenous GnRH pulse/surge, kisspeptin elicits a physiological LH (and FSH) rise — the basis for its use as an IVF egg-maturation trigger and as a probe of hypothalamic function.
Beyond hormone release, kisspeptin modulates limbic brain structures (amygdala, hippocampus, globus pallidus, cingulate) involved in sexual and emotional behaviour, as shown by functional-MRI studies in humans.
How Kisspeptin works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Avoid. The supervised clinical evidence does not validate self-administered grey-market kisspeptin; sourcing, purity and long-term safety are all unknown.
Only within a registered trial or specialist fertility protocol — never self-sourced.
Outside sanctioned reproductive-medicine use, avoid; safety in pregnancy for any non-protocol use is not established.
Kisspeptin acts on the same hypothalamic-pituitary-gonadal axis as GnRH analogues, hCG and gonadotropins; combining them (as in IVF) requires specialist supervision and dosing — not something to layer on at home.
Sex steroids feed back on kisspeptin/GnRH signalling; concurrent use could blunt or alter the gonadotropin response unpredictably.
Tip: Trial doses were generally well-tolerated; this does not extend to unsupervised self-dosing of grey-market product
Tip: Observed with chronic twice-daily dosing; avoid continuous regimens
Tip: Inherent to subcutaneous administration
Tip: Avoid non-pharmaceutical-grade sources entirely — purity, dose and sterility are unverified
Kisspeptin has an evidence score of 3/10 — emerging evidence based on 36 indexed studies. A hypothalamic neuropeptide (from the KISS1 gene) that sits at the top of the reproductive hormone axis — it stimulates GnRH neurons to release LH and FSH. It has a genuinely rigorous human-research record, largely from the Dhillo group at Imperial College London: kisspeptin-54 has been tested as an IVF egg-maturation trigger, in hypothalamic amenorrhea, and for sexual/emotional brain processing. Honest framing: this is legitimate investigational science, NOT an approved drug or a dietary supplement, and the grey-market 'libido peptide' sold online is not the supervised clinical product. Representative study: PMID 26192876.
Dosing for Kisspeptin: No consumer dose — investigational, used only in supervised research/clinical protocols. Trials used weight-based dosing (e.g. kisspeptin-54 6.4-12.8 nmol/kg subcutaneous as a single IVF trigger; kisspeptin-54 1 nmol/kg/h IV infusion in brain-processing studies).
Timing is flexible for Kisspeptin — consistent daily use matters more than the time of day. Dosing is entirely protocol-specific in research settings (e.g.
No consumer dose of Kisspeptin is endorsed, so there is no dose at which it can be called safe. Talk to a healthcare provider before taking it. Reported side effects include unknown effects from impure/mislabelled grey-market product, well-tolerated in supervised trials (no serious adverse events reported), tachyphylaxis (loss of LH response) with repeated dosing. How often they occur is not established for all of them. Use caution if any of these apply to you: Not for self-administration — investigational research peptide; Pregnancy/breastfeeding (outside its supervised reproductive use); Known hypersensitivity to the peptide or formulation excipients.
HCG (Human Chorionic Gonadotropin)
Too few graded studiesA placental glycoprotein hormone that acts as a long-acting LH analogue: it binds the LH/CG receptor on testicular Leydig cells (and ovarian theca cells) to drive sex-steroid production. Honest appraisal: it is genuinely well-established for inducing ovulation/the final-maturation 'trigger' in female fertility, for inducing spermatogenesis in men with hypogonadotropic hypogonadism. Clinical use of hCG depends on the diagnosis and the exact product’s prescribing information. Evidence for adding hCG to testosterone treatment is more limited: a short study measured intratesticular testosterone, not pregnancy or live-birth outcomes. It does not establish that fertility will be preserved during testosterone therapy. Its proven benefits are confined to the gonadal axis — it does not improve systemic longevity or healthspan, and grey-market/compounded sourcing carries real risks.
PT-141
Too few graded studiesA melanocortin-receptor (MC4R) agonist peptide for low sexual desire. Important honest framing: unlike most 'research peptides', bremelanotide is an FDA-APPROVED prescription drug — Vyleesi, approved 2019 — for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, self-injected subcutaneously on-demand. It has real phase-3 RCTs (the RECONNECT program). The catch: the approved-trial benefit was statistically significant but small (a fraction of a point on desire scales), nausea is very common, and it transiently raises blood pressure. Grey-market 'PT-141' vials sold online are NOT the approved drug and are unregulated.
Enclomiphene
Too few graded studiesThe trans-isomer of clomiphene — a selective estrogen receptor modulator (SERM) used investigationally as a testosterone therapy. By blocking estrogen feedback at the hypothalamus it raises LH, FSH, and endogenous testosterone. Honest appraisal: Phase-2/3 RCTs show it raises testosterone — but it is NOT FDA-approved (Androxal failed to gain approval) and is compounded, and there are NO long-term hard-outcome trials (cardiovascular, bone, mortality).
Gonadorelin
Too few graded studiesA synthetic copy of gonadotropin-releasing hormone (GnRH), the hypothalamic decapeptide that drives the pituitary to release LH and FSH. Honest appraisal: it has genuine, trial-backed roles as a diagnostic agent (the GnRH/gonadorelin stimulation test) and — delivered in pulses by an infusion pump — for inducing ovulation in hypothalamic amenorrhea and spermatogenesis in men with congenital hypogonadotropic hypogonadism. Its now-trendy use in men's TRT clinics (compounded, to 'maintain testosterone/fertility' alongside testosterone, often replacing hCG) is largely off-label and has NOT been validated in controlled trials for that purpose.
Explore: Best supplements for Women's HealthBest supplements for Men's Health
Reviewed by Dr. Baher Al Hakim · Last reviewed June 2026 · evidence from 36 studies · how we score · editorial policy
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Tap node to isolate • Pinch to zoom • Tap edge for research